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Bacillus Calmette-Guerin (BCG) enhances monocyte- and
lymphocyte-mediated bladder tumour cell killing
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Summary A cytotoxicity assay was used to study the action of bacillus Calmette-Guerin (BCG) and
cytokines on four human bladder cancer cell lines. Monocytes and lymphocytes from peripheral blood were
incubated with or without BCG or cytokines for 24 h, after which [3H]thymidine-labelled target cells were
added and the 72 h percentage specific release determined. BCG had a direct cytotoxic effect against tumour
cells and significantly enhanced monocyte/macrophage and enhanced lymphocyte cytotoxicity against one cell
line (UCRU-BL-17). Supernatants (SNs) from BCG-activated monocytes/macrophages and lymphocytes in-
creased the percentage specific release of [3H]thymidine from UCRU-BL-17 cells. Interferon alpha (IFN-a) and
interleukin 2 (IL-2) were cytotoxic towards UCRU-BL-17. No synergy occurred between BCG and cytokines
at the concentrations tested. The results suggest that BCG is superior to IFN-a, interferon gamma (IFN-y) and
IL-2 in enhancing cell-mediated cytotoxicity.
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Since the first report of the use of intravesical BCG for the
treatment of recurrent superficial bladder tumours (Morales
et al., 1976), clinical trials have confirmed that BCG is an
effective immunomodulator which provides superior results
to those from chemotherapy (Lamm, 1992). However, the
mechanism of action of BCG remains unclear and therapy
may cause significant side-effects (Lamm et al., 1992).
Interferons have immunomodulatory and antiproliferative
effects and may stimulate phagocytosis by polymorpho-
nuclear leucocytes and increase macrophage and natural
killer (NK) cell activity (Torti and Lum, 1987). IFN-a has
been used successfully clinically for the treatment of
superficial bladder cancer, and patient responses are achieved
with minimal local and systemic toxicity (Torti et al., 1988).
IFN-y (Prescott et al., 1990) and IL-2 (De Jong et al., 1990)
are detected in the urine as part of the local immune response
to BCG therapy.
In normal human urothelium T lymphocytes are present
within the mucosal lining of the ureter and urinary bladder
(El-Demiry et al., 1986). Most of these CD3+ T lymphocytes
are CD8+ (suppressor/cytotoxic), although CD4+ (helper/
inducer) cells are present. Monocytes/macrophages are found
less frequently.
After repeated BCG instillations for superficial bladder
cancer, mononuclear infiltrates are induced in the bladder
wall of the patient. Infiltrating cells include T lymphocytes
and smaller numbers ofmacrophages and B lymphocytes (De
Boer et al., 1991a). Analysis of mucosal bladder leucocyte
subpopulations shows that most cells are lymphocytes which
are associated with macrophages and eosinophils (Peuchmaur
et al., 1991). The major leucocyte subpopulation is the CD4+
T lymphocyte, while NK cells are uncommon and do not
appear to make a major contribution to the anti-tumour
activity of BCG (Ratliff et al., 1986).
Clinical studies showed a marked increase in the number
of leucocytes, mostly granulocytes, in the urine 24 h after
repeated BCG instillations (De Boer et al., 1991b).
Monocytes/macrophages and lymphocytes, mostly CD4+ T
cells, were also present. After treatment, the absolute
numbers of anl subpopulations increased, but the increase in
monocytes/macrophages was most marked.
As monocytes/macrophages and lymphocytes appeared to
be the major leucocyte subpopulations involved in the
immune response to BCG, we developed a cytotoxicity assay
in which monocytes and lymphocytes were pretreated with
BCG and cytokines and then co-incubated with bladder
tumour cells to determine the anti-tumour activity ofimmune
cells.
Materials and methods
Target cells
The UCRU-BL-17 cell line was derived from a transitional
cell carcinoma (Russell et al., 1988) and the 5637, T24 and
J82 cell lines were obtained from the American Type Culture
Collection (ATCC, Bethesda, MD, USA). The cells were
grown in RPMI-1640 (UCRU-BL-17, 5637, T24) or MEM
(J82) (P.A. Biologicals, Sydney, Australia) with 10% foetal
bovine serum (FBS), 25 mM Hepes, 4 mM glutamine and 2%
solution PS (penicillin G 5000 U ml-' streptomycin sulphate
5000 fg ml-') [all from Commonwealth Serum Laboratories
(CSL), Victoria, Australia] and were mycoplasma free (Gen-
probe, CA, USA).
BCG and cytokines
BCG, living organisms of an attenuated strain of Mycobac-
terium tuberculosis [Pasteur strain, 7-15 x 106 colony form-
ing units (c.f.u.) mg-'], was obtained from CSL. Human,
recombinant cytokines included IFN-a2b (Schering Corpora-
tion, NJ, USA) and IL-2 and IFN-' (both from Boehringer
Mannheim, Mannheim, Germany).
Monocyte and lymphocyte isolation
Monocytes and lymphocytes were isolated from healthy
volunteers' peripheral blood, which was collected into EDTA
Vacutainers (Becton Dickinson, NJ, USA). Mantoux tests
identified donors who were positive for sensitivity to
mycobacteria. Monocytes were isolated according to the
Nycodenz monocytes (Nycomed, Oslo, Norway) separation
procedure. The monocyte-depleted Nycodenz pellet was
resuspended in Hank's balanced salt solution without cal-
cium and magnesium (HBSS) (P.A. Biologicals) and lym-
phocytes were then isolated from it by the Ficoll-Paque
(Pharmacia, Uppsala, Sweden) method. The washed Ficoll
interface was plated in cell culture medium for 1 h at 37'C to
remove adherent cells. Peripheral blood mononuclear cells
(PBMCs) were isolated according to the Ficoll-Paque pro-
tocol.
Correspondence: K Pryor
Received 15 June 1994; revised 22 November 1994; accepted 25
November 1994.BCG enhances bladdertumour cell killing
K Pryor etal
802
Flow cytometry
The purity of isolated monocytes and lymphocytes was
estimated by flow cytometry (Profile 11, Coulter, FL, USA).
Monoclonal antibodies (MAbs) were linked with fluorescein
isothiocyanate (FITC) or phycoerythrin (PE). Monocytes and
lymphocytes were stained for CD14 (Leu-M3-PE, mono-
cytes), CD16 (Leu- lla-FITC, NK cells), CD2 (TIl-FITC, T
lymphocytes) and CD20 (Bl-FITC, B lymphocytes). The
negative controls were CD1 (T6-FITC, thymocytes) and
MsIgGl-PE. The cells were stained with MAbs for 30 min at
4°C. MAbs of the Leu series were obtained from Becton
Dickinson (CA, USA) and T6, TI 1, Bi and MsIgGl-PE
were from Coulter. Within the monocyte population there
were 78% CD14, 27% CD16, 2% CD20 and 15% CD2
positive cells, while the lymphocyte population contained
63% CD2-positive, 8% CD20-positive, 26% CD16-positive
and 4% CD14-positive cells. To separate T lymphocytes and
NK cells, lymphocytes isolated using our protocol (described
above) were stained with CD16 and CD3 (Leu-4, T lym-
phocytes) for 30 min on ice. The lymphocytes were then
sorted by flow cytometry (Epics V, Coulter) into a T lym-
phocyte (97% pure) and an NK cell (94% pure) group.
Cytotoxicity assay
The assay detected the cytolytic activity of monocytes and
lymphocytes (effectors) by the release of a DNA radiolabel
from the target cells. [3H]Thymidine was selected for its low
background release over long incubation periods as sig-
nificant macrophage cytotoxicity cannot be measured before
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15 h (De Weger et al., 1986). For this reason the standard 4 h
chromium 5'Cr-release assay was not chosen. Effectors were
incubated in 96-well flat-bottomed tissue culture plates (Cor-
ning, NY, USA) for 24 h at 37°C. Monocytes were called
monocytes/macrophages after plating in tissue culture condi-
tions. BCG (5, 50, 250 or 500figml-') and/or cytokines (10,
100 or 1000 U ml-') were then added to the plated effectors
in triplicate wells for 24 h. The effects of BCG and IFN-a2b
individually and in combination were calculated (Goldstein et
al., 1989) to determine whether they were supra-additive.
Target cells were plated at 3 x 106 targets in 75 cm2 tissue
culture flasks (Coming) for 24 h then labelled while in the
exponential growth phase with 60jiCi of [3H]thymidine
(specific activity 5.0 Ci mmol-'; Amersham, IL, USA) for
24 h at 37°C. The labelled cells were passaged with try-
psin-EDTA [0.5% trypsin, 5.3 mM tetrasodium EDTA
(10 x); Gibco, NY, USA] then added to the effectors at an
effector-target (E/T) ratio of 10:1 for 72 h at 37°C. This time
frame was chosen as significant macrophage cytotoxicity can-
not be measured before 15 h (De Weger et al., 1986) while
BCG-induced killer activity in PBMCs has been shown to
appear within 24 h and decrease after 72 h (Koga et al.,
1991). The optimal E/T ratio for maximising percentage
specific release of [3H]thymidine was predetermined (data not
shown). There were 3000-9000 targets per well, depending
on the target cell selected and the monocyte yield. In some
experiments, effectors were incubated in 24 well flat-bottomed
tissue culture plates (Corning), then BCG (250 or 500
jigml-') was added to the plated effectors for 24, 48 or 72 h.
The filtered SNs were added to labelled UCRU-BL-17 target
cells plated in separate 96-well flat-bottomed tissue culture
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Figure 1 The percentage specific release of incorporated [3H]thymidine by bladder tumour cells UCRU-BL-17 (a), 5637 (b), T24
(c) and J82 (d) increases after a 72 h incubation with BCG. A dose-response effect is seen for T24 cells (r2 = 0.98, P = 0.0012) and
J82 cells (r2 = 0.912, P = 0.0113). Results are expressed as the mean ± the standard error (s.e.) of the number of experiments (n)
(*P<0.05).
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plates. After 72 h the plates were centrifuged and the SNs
counted in the Pico-Fluor 40 scintillation fluid (Packard,
Groningen, The Netherlands) on a Tri-Carb 1500 liquid
scintillation analyser (Packard). Spontaneous release was
measured in target cells cultured in medium alone and max-
imum release in cells which had been lysed in 1% sodium
dodecyl sulphate (SDS). The percentage specific release was
calculated as:
Specific release (%) =
d.p.m. test release - d.p.m. spontaneous release
d.p.m. maximal release - d.p.m. spontaneous release
a
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where d.p.m. = disintegrations per minute.
Different bladder lines showed different mean percentage
spontaneous (background) release of [3H]thymidine as fol-
lows: UCRU-BL-17, 18.5 + 1.4; 5637, 37.0 ± 2.5; T24,
9.2 + 1.5; and J82, 19.6 ± 2.1.
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Cell counts
To determine the effect of BCG on cell number, BCG was
added to plated tumour cells for 72 h. Cells were washed
twice with phosphate-buffered saline (PBS), detached with
trypsin-EDTA and counted by 10% trypan blue (Flow
Laboratories, Irvine, UK) exclusion using a Neubauer
haemocytometer. Cell number and cell viability were deter-
mined.
Statistical methods
The data were analysed using the Mann-Whitney U-test.
Within each experiment (n) there were three replicate wells
per treatment. The results were expressed as the mean of the
percentage specific releases ± the standard error (s.e.). A
regression analysis was performed for data which concerned
a dose-response effect.
cn
+1
q)
.0
E
z
6U
40
20
BCG (gg ml-1)
= 0
m 50
M 250
M 500
T T
Specific release (%)
(n = 4)
I
Viable cell counts (x 10 000)
(n=3)
Effects ofBCG alone
The four target cell lines, UCRU-BL-17, 5637, T24 and J82,
were incubated for 72 h at 37°C with 5, 50, 250 or
500 jig ml- l BCG. BCG increased the percentage specific
release of [3H]thymidine from the targets and for the T24
(r2 = 0.98, P = 0.0012) and J82 (r2 = 0.912, P = 0.0113) cell
lines in a dose-dependent manner (Figure 1) (r2 = 0.82,
P= 0.0343, for UCRU-BL-17; r2 = 0.218, P= 0.5332, for
5637). Decreasing significant P-values with increasing BCG
were seen for the T24 cells (5-50 ggml-', P=0.1747;
5-250 jg ml-', P = 0.0268; and 5-500 ggml-', P = 0.0062).
To confirm that the release of [3H]thymidine represented a
cytotoxic effect, we selected two cell lines UCRU-BL-17,
which was sensitive to effector-mediated killing, and J82,
which showed a dose-dependent direct response to BCG, and
exposed them to BCG for 72 h to compare the cytotoxicity
assay method with cell counts (Figure 2). For both cell lines,
counts significantly decreased (for UCRU-BL-17 P = 0.0374
with BCG 2501gmlP' and P=0.0163 with BCG 500 jg
ml-', r2=0.679, P=0.1758; for J82 P=0.0051 with BCG
25OjigmI' and P=0.0039 with BCG 500figmlP', r2=
0.862, P = 0.0716) and percentage specific release increased
(for UCRU-BL-17 P = 0.0209 with both 250 and 500 Ig
ml-' BCG, r2=0.789, P=0.1116; for J82 P=0.0209 with
50, 250 and 500jigml-' BCG, r2=0.594, P=0.229) with
increasing BCG concentration. We found no increase in the
percentage of dead cells with increasing BCG at the concent-
rations tested, indicating that lysis was complete (data not
shown).
To determine whether a donor's previous exposure to BCG
made their immune cells more responsive to BCG in a cell
culture system with UCRU-BL-17 target cells, effector cells
were isolated from peripheral blood from healthy donors of
different Mantoux status. We selected a group of six donors,
Figure 2 Increasing BCG concentration caused an increase in
the percentage specific release of incorporated [3H]thymidine and
a decrease in cell counts for UCRU-BL-17 (a) and J82 (b) (for
UCRU-BL-17: for percentage specific release P = 0.0209 with
BCG 250 and 500 jigml-'; for cell counts P = 0.0374 with BCG
250Ojgml1, P=0.0163 with BCG 500 jgml-'; for J82: for
percentage specific release P=0.0209 for BCG 50, 250 and
50ogIgml-'; for cell counts P=0.0051 for BCG 250 igml-',
P=0.0039 for BCG 500jgml-') (*P<0.05).
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Figure 3 Monocytes and lymphocytes isolated from Mantoux
negative donors (I -ve, 2 -ve), Mantoux-positive donors
(3 + ve, 4 + ve) and donors who had had a BCG injection in the
last 12 months (5 BCG, 6 BCG) were stimulated with
250 jig ml-' BCG. No difference was detected in the cytotoxicity
of effectors from different donors towards UCRU-BL-17 target
cells (-ve vs + ve, P = 0.7488; -ve vs BCG, P = 0.7488; + ve
vs BCG, P = 0.631). The control was UCRU-BL-17 cells alone.
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of whom two were Mantoux negative (- ve), two Mantoux
positive (+ ve) and two had had a recent BCG injection
following a negative Mantoux test (BCG). We found no
correlation between in vitro effector response to BCG and
donor exposure to BCG (-ve vs + ve; P = 0.7488; -ve vs
BCG, P = 0.7488; +ve vs BCG, P = 0.631) (Figure 3).
Unstimulated lymphocytes had a significantly higher cyto-
toxic activity (19.6% ± 4.6%) than unstimulated monocytes/
macrophages (6.8%- 1.6%) (P = 0.0041) against the cell line
UCRU-BL-17, and both were significantly higher than the
spontaneous release by target cells alone (monocytes vs con-
trol P = 0.0013; lymphocytes vs control P = 0.0001) (Figure
4). This trend was observed for the 5637 and J82 cell lines
but was not statistically significant (data not shown). As the
UCRU-BL-17 cell line appeared to be more sensitive to
effector-mediated killing, it was selected to test BCG- and
cytokine-enhanced effector cytotoxicity. The cytotoxic acti-
vity of both monocytes/macrophages and lymphocytes
against UCRU-BL-17 target cells was increased by pre-
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exposure to BCG (5, 50 or 250tig ml-') (Figure 5).
Monocyte/macrophage cytotoxicity was significantly en-
hanced by BCG in a dose-dependent fashion (from 7.8% ±
2.1% to 16.3%±2.4% with BCG 5fgml-', P=0.0093; to
25.8%±3.0% with 250igml-l and 25.9%0±3.4% with
500 .tgml- , P=0.0001 for both, r2=0.73, P=0.1455).
Lymphocyte cytotoxicity increased at the higher concentra-
tions (from 21.3% ± 4.4% to 30.6% ± 6.3% with 250 tg
ml-' BCG, P = 0.2517, r2 = 0.869, P = 0.0676). Results
obtained from experiments with the 5637, T24 and J82 cell
lines did not demonstrate a consistent trend (data not
shown). When the filtered SNs of BCG-treated monocytes/
macrophages or lymphocytes were added to UCRU-BL-17
target cells, the percentage specific release was significantly
higher than that from targets incubated with SNs from unt-
reated effectors (P = 0.0209 for each BCG concentration and
incubation time for both effectors) (Figure 6). Similar
significant differences were seen when using the J82 target
line (data not shown).
To determine whether BCG pretreatment made target cells
more susceptible to effector-mediated cytolysis, UCRU-BL-
17 cells were pretreated for 48 h with BCG. Treated targets
were no more susceptible than untreated targets to lysis by
BCG- or cytokine-stimulated monocytes/macrophages or
lymphocytes (data not shown).
Monocytes and lymphocytes were isolated from the
peripheral blood of two pretherapy bladder cancer patients.
The patients were male, 61 (patient 1) and 74 (patient 2)
years old, and information on previous exposure to BCG was
not available from their medical records. BCG-stimulated
effector cells isolated from patient 2 but not from patient 1
(monocytes, P = 0.009; lymphocytes, P = 0.0947) (Figure 7).
(n= 14)
Figure 4 Unstimulated lymphocytes caused a significantly higher
72 h percentage specific release by target cells UCRU-BL- 17 than
unstimulated monocytes (P = 0.0041). The [3H]thymidine release
in the presence of both effector types was significantly higher
than the spontaneous release by the control, UCRU-BL-17 target
cells alone (monocytes, P= 0.0013; lymphocytes, P= 0.0001)
(*P<0.05).
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Figure 5 UCRU-BL-17 cells were co-cultured with BCG-treated
monocytes (a) or lymphocytes (b) for 72 h. Monocyte/macro-
phage cytotoxicity towards UCRU-BL-17 cells was significantly
enhanced by BCG (P=0.0093 with 5 jigmml BCG; P=0.0001
with 250 or 500 ig ml-' BCG). Lymphocyte cytotoxicity in-
creased from 21.3%± 4.4% to 30.6%± 6.3% with 250jigml-'
BCG (P
= 0.2517) (*P<0.05).
Effects ofcytokines
As the enhanced cytotoxicity in the presence of BCG
appeared to be mediated by cytokine release, we tested the
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Figure 6 When filtered SNs from monocytes/macrophages (a)
and lymphocytes (b) were added to UCRU-BL-17 target cells, the
tar-get cell lysis was significantly greater if the effectors had been
incubated with BCG (P = 0.0209). There was no difference
between the incubation times (24, 48 or 72 h) or BCG doses (250
or 500 gml-') tested (*P<0.05).
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The cytokines IFN-a2b, IFN-y and IL-2 at concentrations of
10, 100 or 1000 Uml-I were added to the tumour target cells
alone (control) or with effectors. IFN-a2b and IL-2 caused
an increase in percentage specific release by UCRU-BL-17
cells (for IFN-o2b: for an increase of 10 to 100 U ml-',
P=0.5715, 10 to 1000Uml-', P=0.5119, r2=0.675,
P=0.1783; for IFN-7y: 10 to l00UmlP', P=1, 10 to
1000 U ml-', P = 0.8046, r2= 0.068, P = 0.7391; for IL-2: 10
to 100Uml'l, P=0.8977, r2=919, P=0.1836), but this
was not statistically significant (Table I). There was no
observed increase for the other three cell lines (data not
shown). IFN-a2b, IFN-y and IL-2 did not significantly
enhance monocyte/macrophage or lymphocyte killing of any
of our cell lines at the doses tested (data not shown).
Combinations ofBCG and cytokines
The effects of BCG combined with IFN-m2b, IFN-'y or IL-2
at the concentrations stated above were investigated using the
four cell lines. In case the effects were due to timing, BCG
and IFN-a2b were added together or sequentially, one 6 h
after the other, in either order. We found neither evidence of
supra-additivity nor any advantage in adding the biological
response modifiers together as compared with separately in
either order (data not shown).
T-cell/natural killer (NK) cell cytotoxicity
T cells and NK cells were compared with peripheral blood
mononuclear cells (PBMCs) and lymphocytes in the above
assay at 72 h and 144 h (Figure 8). The percentage specific
release for all populations increased with time and BCG
concentration. Addition of 250pgml-' BCG to effectors in-
creased their 72 h percentage specific release as follows: con-
trol, 0% to 7.2%; PBMCs, 16.1% to 30.6%; lymphocytes,
11.7% to 25.4%; T cells, 4.4% to 6.3%; and T cells + 20%
NK cells, 5.7% to 7.2%. These increases were not statis-
tically significant (P = 0.1732). At 144 h the percentage
specific release in all effector populations strongly correlated
with BCG concentration (control, r2 = 0.727, P = 0.3499;
PBMCs, r2= 1, P =0.0066; lymphocytes, r2= 0.996, P =
0.0421; T cells, r2=0.941, P=0.1557; and T cells+20%
NK cells, r2 = 0.998, P = 0.0275).
Discussion
BCG enhanced cytotoxic activity of monocytes and lym-
phocytes against bladder cancer cell lines in vitro and also
had a small direct effect on these target cells. In four bladder
tumour target lines, BCG mediated an increase in percentage
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specific release, accompanied by a decrease in cell numbers
but not cell viability, suggesting an antiproliferative rather
than a cytotoxic effect. BCG can bind in a dose-dependent
manner to T24 cells (Mitzutani et al., 1991) and is inter-
nalised by both mouse and human bladder tumour cells
(Becich et al., 1991). Although direct cytotoxicity of BCG or
cytokines alone was not demonstrable against bladder cancer
cell lines (Bohle et al., 1993), it could result from release of
bacterial components during BCG degradation or from pro-
liferation of intracellular bacteria.
Previous exposure of a donor to BCG failed to enhance in
vitro BCG-mediated effector cytotoxicity, but effectors from
two pretherapy bladder cancer patients showed different res-
ponses. An understanding of the basis of patient response
variation may help to predict who would benefit from BCG
immunotherapy.
Monocytes and lymphocytes have been identified in
immune infiltrates in the bladder following BCG administra-
tion (De Boer et al., 1991a; Peuchmaur et al., 1991) and an
intact thymus-dependent immune response is required for the
anti-tumour activity of BCG (Ratliff et al., 1987; Ratliff,
1992). Flow cytometric analysis indicated that lymphocyte
fractions used in our study contained T, B and NK cells and
some polymorphonuclear (PMN) cells, while the monocyte
population was more homogeneous (78% CD14+). PBMCs
and unsorted lymphocytes were more cytotoxic than sorted T
cells or T cells+ 20% NK cells, which showed a slower
response, requiring over 144 h. Each effector group was more
cytotoxic at 144 h than at 72 h. Others have shown that
PBMCs incubated with BCG increase cytotoxicity to a max-
imum at 7 days (Bohle et al., 1993) but are unable to
demonstrate NK-mediated killing ofbladder cancer cell lines.
The greater cytotoxic activity of unstimulated lymphocytes
compared with unstimulated monocytes/macrophages may be
due to cytokine release by effectors in the lymphocyte frac-
Table I Effect of cytokines on percentage specific release of
[3H]thymidine by UCRU-BL-17 bladder tumour cells
Concentration (Uml-')
Cytokine 10 100 1000
IFN-m2b 2.7 ± 1.0 4.0 ± 1.0 6.4 ± 2.4
(n = 9-18)
IFN-y 3.0+ 2.0 3.7 + 1.5 3.1 + 1.0
(n =6-14)
IL-2 2.5 1.2 6.6 3.2 Not tested
(n= 12-14)
EControl 72 h
Control 144 h
PBMCs 72 h
XPBMCs 144 h
120 XLymphocytes 72 h
U lIT
_iToeNs 1U h s
- Tcells +20%NK 72 h
T cell +20% NKIh
4I-
0 400 500
Figure 7 Monocytes (circles) and lymphocytes (squares) isolated
from the blood of two pretherapy bladder cancer patients
(patient 1, open symbols; patient 2, closed symbols) were
stimulated with BCG, but only those from one patient became
more cytotoxic towards UCRU-BL-17 tumour cells (monocytes,
P = 0.009; lymphocytes, P = 0.0947). As each sample was only
available once, the results are expressed as the mean of triplicate
wells in a single experiment (*P<0.05).
*50
BCG (Sg m16)
250
(n- 1)
Figure 8 The percentage specific release by UCRU-BL-17 target
cells co-cultured with PBMCs, lymphocytes, T cells and T
cells + 20% NK cells increased with increasing BCG concentra-
tion and incubation time, but this was not statistically significant
(O vs 50 Agml-' BCG, P=0.2568; 0 vs 250 tgmlh' BCG,
P=0.1041; 72h vs 144h: no BCG, P=0.2101; 50 lsgml-' BCG,
P=0.4647; 250 lgml-' BCG, P=0.3472. The results are ex-
pressed as the mean of triplicate samples in a single experiment.
n - I
v -T.. I -v - -
I IBCGenhances bladder tumourcell killing
K Pryor etal
806
tion. We found that SNs from BCG-activated monocytes/
macrophages and lymphocytes increased target cell lysis,
indicating that BCG cytotoxicity is largely cytokine
mediated. Possible candidate cytokines include tumour nec-
rosis factor alpha (TNF-a), IFN-7, IL-1p and IL-6 (Kurisu et
al., 1995). This is supported by clinical studies which show
that BCG therapy induces the presence of IL-1, IL-2, IL-6,
TNF-a (De Boer et al., 1992) and IFN-y (Prescott et al.,
1990) in urine, probably derived from activated lymphocytes
and, similarly, IFN-y, IL-2, TNF-o and TNF-P are found in
SNs of BCG-activated PBMCs in vitro (Thanhauser et al.,
1993). In other studies, CD8+/CD56+ lymphocytes, but not
CD4+ cells or macrophages, have been found to be respon-
sible for BCG-induced cytolysis (Thanhauser et al., 1993).
Both IFN-a2b and IL-2, but not IFN-y, caused a small
increase in the percentage specific release by UCRU-BL-17
cells. The mechanism underlying these effects was not clear,
although IFN-a has proven effectiveness in vivo (Torti et al.,
1988). Others have shown that IL-2 at 10Uml' induces
LAK activity against bladder cancer cell lines after 3 days,
but that maximum activity requires 6 days with 1000 U ml1'
(Jackson et al., 1992). Tumour cells modified to express IL-2
and injected into tumour-bearing mice have been shown to
give better anti-tumour effects than cisplatin or IFN-y-
producing cells against MBT2 mouse tumours, but no
memory was established in 'cured' mice (Connor et al., 1993).
IL-2 also contributes to the maturation of effector cells and
stimulates IFN-y production, inducing activation of mac-
rophages and cytotoxic T cells (Ikemoto et al., 1990). The
increase to maximum cytotoxicity by monocytes incubated
with IL-2 occurs at 8-16 days (Higashi et al., 1992). The
assay time which we used may not be sufficient to demon-
strate maximum IL-2-mediated increases in effector cytotox-
icity.
In the assay used, BCG was more efficient than cytokines
in stimulating effector cells alone. The response of mac-
rophages has been shown to depend on the activating agent.
Thus, lymphokine-triggered cytotoxic activity in bone mar-
row-derived phagocytes declines after 24 h, but that elicited
by bacteria persists (Keller et al., 1990). Furthermore, the
secretion of IL-6 and prostaglandin E2 (PGE2) is enhanced by
bacteria but not by lymphokines. In our experiments, a
combination ofBCG and cytokines was not supra-additive at
the concentrations tested and an isobolographic analysis was
not therefore justified (Goldstein et al., 1989).
The bladder cancer lines used in this study differed in
susceptibility to cytotoxic effects of BCG. Preincubation with
BCG induced a dose-dependent increase in cytotoxic activity
towards UCRU-BL,4l7, but not towards 5637, T24 or J82
bladder cancer cells. Others have also found that effector cell
killing is independent of the histological grade of the parent
tumour and the donor of the effector cells (Jackson et al.,
1992). Possible explanations for differences in target cell
susceptibility relate to expression of cytokine receptors or
tumour-associated antigens. The UCRU-BL-17 line has been
established much more recently than the other cell lines,
which may have undergone changes in resistance over their
long period of tissue culture.
The mechanisms of BCG action are unclear but involve
both direct effects possibly mediated via internalised bacteria
and indirect immune effects involving immune infiltrates
found in the bladder wall and urine of patients treated with
BCG instillations. In vitro, the cytotoxic effect ofmonocytes/
macrophages and lymphocytes is significantly enhanced by
BCG, indicating that this could be an important indirect
immune effect of BCG. Further work is needed to clarify the
role of effector cells, using specific defined leucocyte sub-
populations, and to understand the differential sensitivity of
target cells to cytotoxic effects.
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